Table 1.
Coagulation parameters of the study patients
| LVO AIS with COVID-19 n = 3 |
LVO AIS without COVID-19 n = 4 |
AMI N = 1 |
Normal range | |
|---|---|---|---|---|
| PLT count, × 103/μL | 633 | 150–450 | ||
| (n. of pts with available data) | (3/3) | (4/4) | ||
| Mean | 199.33 | 231.0 | ||
| Median | 184.0 | 228.0 | ||
| MPV, fL | 8.0 | 7.2–13.0 | ||
| (n. of pts with available data) | (3/3) | (4/4) | ||
| Mean | 9.5 | 8.1 | ||
| Median | 9.5 | 8.2 | ||
| INR | 1.31 | 0.8–1.2 | ||
| (n. of pts with available data) | (3/3) | (2/4) | ||
| Mean | 1.01 | 1.0 | ||
| Median | 0.95 | 1.0 | ||
| aPTT | 0.83 | 0.8–1.2 | ||
| (n. of pts with available data) | (3/3) | (2/4) | ||
| Mean | 0.89 | 0.94 | ||
| Median | 0.96 | 0.92 | ||
| d-dimer, μg/L | n/a | 390 | 0–550 | |
| (n. of pts with available data) | (3/4) | |||
| Mean | 1646.33 | |||
| Median | 805.0 | |||
| Fibrinogen, μg/dL | 277 | 200–400 | ||
| (n. of pts with available data) | (3/3) | (3/4) | ||
| Mean | 476.33 | 345.33 | ||
| Median | 556.00 | 334.0 | ||
| ATIII, % | n/a | n/a | 94 | 80–120 |
| (n. of pts with available data) | ||||
| Mean | ||||
| Median | ||||
| FVIII, % | n/a | 58–130 | ||
| (n. of pts with available data) | (1/3) | (3/4) | ||
| Mean | 83.30 | 55.97 | ||
| Median | 54.90 | |||
| vWFAg, % | n/a | 41–130 | ||
| (n. of pts with available data) | (1/3) | (3/4) | ||
| Mean | 221.90 | 136.33 | ||
| Median | 138.0 | |||
| vWFRCo, % | n/a | 41–124 | ||
| (n. of pts with available data) | (1/3) | (3/4) | ||
| Mean | 261.60 | 127.67 | ||
| Median | 140.90 | |||
| FXIII, % | n/a | 64–140 | ||
| (n. of pts with available data) | (1/3) | (3/4) | ||
| Mean | 107.80 | 83.10 | ||
| Median | 82.50 |
Proportions in round brackets represent the number of patients with available data
aPTT, activated partial thromboplastin time; INR, international normalized ratio; MPV, mean platelet volume; n/a, not available; PLT, platelet; vWFAg, von Willebrand factor antigen; vWFRCo, von Willebrand factor ristocetin cofactor